Answers are grounded in this paper and cite their sources.
Aims: Vulvovaginal candidiasis is one of the most common complaints in the medical clinic. In recent years, due to the increasing frequency of non-albicans species, the number of cases of therapeutic failure has increased considerably, generating the need for research to learn the profile of yeasts isolated in vulvovaginal candidiasis. The aims of this study were to collect samples of vaginal secretion, verify the presence of yeast, identify the species of yeast, and verify their in vitro susceptibility profile against six antifungal agents – amphotericin B, nystatin, fluconazole,itraconazole, ketoconazole and voriconazole. Materials and Methods: Vaginal secretion was collected from 130 patients with symptoms characteristic of vulvovaginal candidiasis (VVC). For amphotericin B, fluconazole, itraconazole, ketoconazole and voriconazole, the in-vitro tests were carried out using the commercial Etest susceptibility testing kit; for nystatin the disk diffusion method was used. Results: The yeasts isolated were: Candida albicans (90%), C. glabrata (5%), C.parapsilosis (3%) and C. tropicalis (2%). By the CLSI method, all the isolates were susceptible to fluconazole, ketoconazole, nystatin and voriconazole. Tests showed that 98.8% of the isolates were susceptible to amphotericin B and 97.6% to itraconazole. Conclusion: Although a high number of resistant strains were not found, these studies may help guide physicians to the most convenient therapeutic orientation, conducting treatment specific to the identified yeast species.
No takes yet. Share an insight, caveat, or question.
Moreira et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: